#	Pagina
attuale pagina	/open-h2020/projects/193269/index.html

Opendata, web and dolomites

NEPHSTROM SIGNED

Novel Stromal Cell Therapy for Diabetic Kidney Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

NEPHSTROM project word cloud

Explore the words cloud of the NEPHSTROM project. It provides you a very rough idea of what is the project "NEPHSTROM" about.

animals enormous dialysis stage efficacy placebo centre renal costly trial impacts cd362msc toward optimal improves disease risk socioeconomic benefits orbcel rate action tolerability progression purity albuminuria cell outcomes stabilization gt hyperglycaemia 500 characterisation type infusion filtration plastic pharmacotherapy investigators communicable simultaneously stabilising immunological inform safety versus kidney progressive treatments transplantation name mortality adults 2040 conduct chronic single diabetes allogeneic diabetic adverse trade generate therapy trials adherent bio halting nephstrom function benefit delivers preliminary glomerular 1b demonstrated enabler clinical stromal superior secondary generation dose mainstay reduce dkd population people subsequent mechanisms critically complications protection mesenchymal 2a conventional intravenous million ancillary limited frequently msc economic progresses

Project "NEPHSTROM" data sheet

The following table provides information about the project.

Coordinator	NATIONAL UNIVERSITY OF IRELAND GALWAY Organization address address: UNIVERSITY ROAD city: Galway postcode: H91 website: www.nuigalway.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	http://nephstrom.eu
Total cost	5˙994˙373 €
EC max contribution	5˙994˙373 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2014-two-stage
Funding Scheme	RIA
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2020-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	NATIONAL UNIVERSITY OF IRELAND GALWAY NATIONAL UNIVERSITY OF IRELAND GALWAY Organization address address: UNIVERSITY ROAD city: Galway postcode: H91 website: www.nuigalway.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (Galway)	coordinator	1˙367˙830.00
2	TERUMO BCT EUROPE NV TERUMO BCT EUROPE NV Organization address address: IKAROSLAAN 41 city: ZAVENTEM postcode: 1930 website: www.terumobct.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ZAVENTEM)	participant	599˙812.00
3	ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI Organization address address: VIA MARIO NEGRI 2 city: MILANO postcode: 20156 website: www.marionegri.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	547˙902.00
4	AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII Organization address address: PIAZZA OMS 1 city: BERGAMO postcode: 24127 website: www.ospedaliriuniti.bergamo.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BERGAMO)	participant	546˙472.00
5	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	523˙568.00
6	NHS BLOOD AND TRANSPLANT NHS BLOOD AND TRANSPLANT Organization address address: OAK HOUSE REEDS CRESCENT city: WATFORD postcode: WD24 4QN website: www.nhsbt.nhs.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (WATFORD)	participant	450˙000.00
7	UNIVERSITY HOSPITAL BIRMINGHAM NHS FOUNDATION TRUST UNIVERSITY HOSPITAL BIRMINGHAM NHS FOUNDATION TRUST Organization address address: MINDELSOHN WAY QUEEN ELIZABETH MEDICAL CENTRE city: BIRMINGHAM postcode: B15 2PR website: www.uhb.nhs.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BIRMINGHAM)	participant	431˙875.00
8	BELFAST HEALTH AND SOCIAL CARE TRUST BELFAST HEALTH AND SOCIAL CARE TRUST Organization address address: LISBURN ROAD BELFAST CITY HOSPITAL A FLOOR city: BELFAST postcode: BT9 7AS website: www.belfasttrust.hscni.net/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BELFAST)	participant	415˙000.00
9	ORBSEN THERAPEUTICS LIMITED ORBSEN THERAPEUTICS LIMITED Organization address address: UNIT 1 GALWAY BUSINESS PARK city: Galway postcode: H91 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (Galway)	participant	396˙912.00
10	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	365˙000.00
11	PINTAIL LTD PINTAIL LTD Organization address address: SPRINGHILL AVENUE 77 city: Blackrock postcode: A94 K542 website: www.pintail.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (Blackrock)	participant	200˙000.00
12	THE QUEEN'S UNIVERSITY OF BELFAST THE QUEEN'S UNIVERSITY OF BELFAST Organization address address: UNIVERSITY ROAD LANYON BUILDING city: BELFAST postcode: BT7 1NN website: www.qub.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BELFAST)	participant	150˙000.00

Map

Project objective

Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation represent the mainstay treatments for DKD but are costly and provide only limited protection against adverse outcomes. Mesenchymal Stromal Cell (MSC) therapy is a promising approach to halting the progression of DKD toward end-stage renal failure and may also have ancillary benefits in Type 2 diabetes. In preliminary research, we have demonstrated that a single dose of MSC simultaneously improves kidney function (glomerular filtration rate and albuminuria) as well as hyperglycaemia in animals with DKD. NEPHSTROM will conduct a multi-centre, placebo-controlled clinical trial of a novel MSC therapy for stabilization of progressive DKD, leading to superior clinical outcomes and long-term socioeconomic benefit. A key enabler for this trial is a novel MSC population (CD362MSC, trade name ORBCEL-M) which delivers higher purity and improved characterisation compared to conventional plastic-adherent MSC. The NEPHSTROM Phase 1b/2a clinical trial will investigate the safety, tolerability and preliminary efficacy of a single intravenous infusion of allogeneic ORBCEL-M versus placebo in adults with progressive DKD. NEPHSTROM investigators will also determine the bio-distribution, mechanisms of action, immunological effects and economic impacts associated with ORBCEL-M therapy for DKD. This research will critically inform the optimal design of subsequent Phase 3 trials of ORBCEL-M. Stabilising progressive DKD through NEPHSTROM’s next-generation MSC therapy will reduce the high all-cause mortality and end-stage renal failure risk in people with this chronic non-communicable disease

Deliverables

List of deliverables.
Website	Websites, patent fillings, videos etc.	2020-01-24 09:01:41
Dissemination materials	Websites, patent fillings, videos etc.	2020-01-24 09:01:41

Take a look to the deliverables list in detail: detailed list of NEPHSTROM deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Manuel Alfredo PodestÃ , Giuseppe Remuzzi, Federica Casiraghi Mesenchymal Stromal Cells for Transplant Tolerance published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01287	Frontiers in Immunology 10	2020-01-24
2018	Nga T. Q. Nguyen, Paul Cockwell, Alexander P. Maxwell, Matthew Griffin, Timothy Oâ€™Brien, Ciaran Oâ€™Neill Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England published pages: e0207960, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0207960	PLOS ONE 13/11	2020-01-24
2018	Siobhan M. Hamon, TomÃ¡s P. Griffin, Md Nahidul Islam, Deirdre Wall, Matthew D. Griffin, Paula M. Oâ€™Shea Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD) published pages: , ISSN: 1434-6621, DOI: 10.1515/cclm-2018-0534	Clinical Chemistry and Laboratory Medicine (CCLM) 0/0	2020-01-24
2018	A. Liew, C. Baustian, D. Thomas, E. Vaughan, C. Sanz-NoguÃ©s, M. Creane, X. Chen, S. Alagesan, P. Owens, J. Horan, P. Dockery, M. D. Griffin, A. Duffy, T. Oâ€™Brien Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody published pages: 96368971878486, ISSN: 0963-6897, DOI: 10.1177/0963689718784862	Cell Transplantation	2020-01-24
2019	TomÃ¡s Griffin, Md Islam, Liam Blake, Marcia Bell, Matthew Griffin, Paula Oâ€™Shea Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus published pages: 91-99, ISSN: 0018-5043, DOI: 10.1055/a-0794-7026	Hormone and Metabolic Research 51/02	2020-01-24
2018	Norberto Perico, Federica Casiraghi, Giuseppe Remuzzi Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology published pages: 362-375, ISSN: 1046-6673, DOI: 10.1681/ASN.2017070781	Journal of the American Society of Nephrology 29/2	2020-01-24
2018	Muhammad Mosaraf Hossain, David Barua, Vahid Arabkari, Nahidul Islam, Ananya Gupta, Sanjeev Gupta Hyperactivation of nuclear receptor coactivators induces PERK-dependent cell death published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.24451	Oncotarget 9/14	2020-01-24
2018	Eanna P Connaughton, Serika Naicker, Shirley A Hanley, Stephanie M Slevin, John K Eykelenboom, Noel F Lowndes, Timothy O\'Brien, Rhodri Ceredig, Matthew D Griffin, Michael C Dennedy Phenotypic and functional heterogeneity of human intermediate monocytes based on HLA-DR expression published pages: , ISSN: 0818-9641, DOI: 10.1111/imcb.12032	Immunology and Cell Biology	2020-01-24
2018	Paul Lohan, Oliver Treacy, Maurice Morcos, Ellen Donohoe, Yvonne O\'donoghue, Aideen E. Ryan, Stephen J. Elliman, Thomas Ritter, Matthew D. Griffin Interspecies Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the Rat published pages: , ISSN: 1066-5099, DOI: 10.1002/stem.2840	STEM CELLS	2020-01-24
2017	William P. Martin, TomÃ¡s P. Griffin, David W. Lappin, Damian G. Griffin, John P. Ferguson, Timothy O\'Brien, Matthew D. Griffin Influence of Referral to a Combined Diabetology and Nephrology Clinic on Renal Functional Trends and Metabolic Parameters in Adults With Diabetic Kidney Disease published pages: 150-160, ISSN: 2542-4548, DOI: 10.1016/j.mayocpiqo.2017.07.003	Mayo Clinic Proceedings: Innovations, Quality & Outcomes 1/2	2020-01-24
2018	Norberto Perico, Federica Casiraghi, Giuseppe Remuzzi Mesenchymal Stromal Cells for AKI after Cardiac Surgery published pages: ASN.2017111207, ISSN: 1046-6673, DOI: 10.1681/ASN.2017111207	Journal of the American Society of Nephrology	2020-01-24
2018	Senthilkumar Alagesan, Clara Sanz-NoguÃ©s, Xizhe Chen, Michael Creane, Thomas Ritter, Rhodri Ceredig, Timothy O\'Brien, Matthew D Griffin Anti-donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells published pages: 536-548, ISSN: 0818-9641, DOI: 10.1111/imcb.12024	Immunology and Cell Biology 96/5	2020-01-24
2016	Onkar P. Kulkarni, Julia Lichtnekert, Hans-Joachim Anders, Shrikant R. Mulay The Immune System in Tissue Environments Regaining Homeostasis after Injury: Is â€œInflammationâ€ Always Inflammation? published pages: 1-9, ISSN: 0962-9351, DOI: 10.1155/2016/2856213	Mediators of Inflammation 2016	2020-01-24
2017	Paola Romagnani, Giuseppe Remuzzi, Richard Glassock, Adeera Levin, Kitty J. Jager, Marcello Tonelli, Ziad Massy, Christoph Wanner, Hans-Joachim Anders Chronic kidney disease published pages: 17088, ISSN: 2056-676X, DOI: 10.1038/nrdp.2017.88	Nature Reviews Disease Primers 3	2020-01-24
2016	TomÃ¡s P. Griffin, William Patrick Martin, Nahidul Islam, Timothy Oâ€™Brien, Matthew D. Griffin The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease published pages: , ISSN: 1534-4827, DOI: 10.1007/s11892-016-0734-6	Current Diabetes Reports 16/5	2020-01-24
2017	Paul Lohan, Oliver Treacy, Matthew D. Griffin, Thomas Ritter, Aideen E. Ryan Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2017.01626	Frontiers in Immunology 8	2020-01-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEPHSTROM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEPHSTROM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More

SBR (2020)

SMART BONE REGENERATION

Read More

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More